Equities

PZ Cormay SA

CRM:WSE

PZ Cormay SA

Actions
Health CareMedical Equipment and Services
  • Price (PLN)0.544
  • Today's Change-0.012 / -2.16%
  • Shares traded115.56k
  • 1 Year change-26.49%
  • Beta--
Data delayed at least 15 minutes, as of Jul 04 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PZ Cormay SA is a Polish-based producer and wholesaler of diagnostic reagents and a distributor of the laboratory equipment. The Company is engaged in the design, manufacture and distribution of a range of products for clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation and specific protein recognition. It offers drugs, biochemical rapid tests and devices such as vacuettes and tubes. PZ Cormay SA provides also biochemical analyzers: ACCENT-300, ACCENT-200, PRESTIGE 24i and LIVIA; hematological analyzers: MYTHIC 18, among others, and urinalysis apparatus: IChem 100. On September 1, 2014, Orphee SA acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee SA.

  • Revenue in PLN (TTM)84.43m
  • Net income in PLN-6.14m
  • Incorporated2006
  • Employees225.00
  • Location
    PZ Cormay SAul. Wiosenna 22LOMIANKI 05-092PolandPOL
  • Phone+48 227517910
  • Fax+48 227517911
  • Websitehttps://cormay.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Redsense Medical AB (publ)7.49m-2.85m42.51m5.00--5.15--5.68-0.5389-0.53891.411.420.72614.515.023,970,800.00-27.67-18.66-31.75-20.9950.1169.02-38.11-46.282.21--0.00--74.1128.9448.47---23.62--
Cambridge Nutritional Sciences PLC45.71m-16.24m43.89m91.00--0.9336--0.9601-0.0136-0.01050.03850.03910.58573.972.0599,406.59-20.81-10.49-23.88-11.9052.9059.24-35.53-27.404.22-128.470.0225---11.63-1.96-125.12---45.83--
PZ Cormay SA84.43m-6.14m45.81m225.00--0.842--0.5426-0.0729-0.07291.000.64610.87472.184.89375,240.00-6.39-12.12-9.76-17.1840.0639.19-7.31-16.500.7754-11.970.0765---3.673.3335.43---3.97--
Nanexa AB10.90m-26.63m45.94m19.00--1.31--4.22-0.8143-0.81430.32520.68540.2069-33.452.261,521,474.00-50.54-40.77-66.82-48.77124.7077.27-244.28-532.262.14--0.0193--925.42147.00-30.44--39.10--
Feedback plc4.48m-17.62m46.16m24.00--1.02--10.31-0.2614-0.26140.06640.67260.0774--3.7436,916.67-30.44-28.58-32.67-31.7490.6092.61-393.47-299.13----0.00--74.1517.46-37.74--56.22--
Toleranzia AB0.00-2.37m46.37m7.00--0.8052-----0.0405-0.04050.000.7750.00----0.00-4.50-7.45-4.65-7.78------------0.00------11.79--63.90--
Inventionmed SA610.00-2.49m46.64m7.00--8.78--76,460.73-0.0123-0.01230.000.02620.00002--0.000690.10-6.89-17.52-12.24-22.72-11,611.48-48.77-408,403.30-42,256.86---2.140.00---85.01--91.47------
Genedrive PLC1.37m-25.26m46.66m43.00--1.73--33.95-0.0407-0.04070.00220.00980.0658--1.606,325.58-120.84-97.55-197.86-128.51-----1,837.50-797.031.36-7.490.0789--12.24-50.95-10.16--16.72--
Dignitana AB32.33m-6.97m46.77m28.00--40.08--1.45-0.2487-0.24871.150.03841.663.3514.613,175,519.00-35.81-42.21-97.80-68.9169.1166.09-21.55-57.290.3234-8.840.8571--17.9020.5922.52---15.31--
Spineguard SA18.47m-17.91m47.23m24.00--1.58--2.56-0.107-0.1070.11040.12550.38271.284.68179,700.00-37.12-23.69-52.43-42.7372.8975.60-97.00-45.021.73-13.510.3384---22.98-10.65-74.81--89.42--
Ivision Tech SpA40.11m229.62k49.32m146.00214.751.767.031.230.00770.00771.350.9418------64,151.30--------57.67--0.5725--1.222.380.4058--18.59---81.01------
Medinice SA225.00k-5.17m49.40m16.00--1.58--219.56-0.8224-0.82240.03594.970.0059--0.369814,062.50-13.46-12.47-13.77-12.9627.1162.64-2,297.33-1,404.30----0.017---10.71189.32-4.41--177.91--
Medicon Hellas SA85.06m8.80m49.96m98.005.680.68473.020.58740.46520.46524.493.860.6111.882.16--6.736.488.018.1572.1474.4411.0211.21--11.500.3853---3.4110.33-16.688.0824.76--
Implanet SA31.89m-28.59m50.52m41.00------1.58-0.1704-0.17040.1933-0.00420.59310.90834.19182,973.00-53.17-37.44-159.90-86.7456.8359.59-89.65-67.430.2932-24.761.03---7.242.08-88.59---2.20--
Iconovo AB3.19m-15.99m51.02m29.00--1.01--15.97-3.68-3.680.7038.450.0554--1.24292,079.00-27.74-25.43-30.85-28.24234.21134.57-500.63-215.16----0.0666---58.65-9.884.71--34.70--
Laboratoires Euromedis SA145.76m56.14m51.83m54.000.91490.53090.90880.35564.604.6011.667.930.64153.053.92630,347.6024.718.7634.6512.450.533815.5738.526.101.46-26.380.3031---37.18--320.97------
Data as of Jul 04 2024. Currency figures normalised to PZ Cormay SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

1.20%Per cent of shares held by top holders
HolderShares% Held
Generali PTE SAas of 29 Dec 2023968.48k1.15%
St. Galler Kantonalbank AG (Private Banking)as of 31 Jan 202440.00k0.05%
Allianz Polska TFI SAas of 30 Jun 20230.000.00%
Data from 29 Dec 2023 - 31 Jan 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.